The Medical Advisor

Home › Master Guide | Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Last updated: November 2026 | Purpose: education, not individual medical advice One starting point for OneDayMD and the wider One Day Media Network: nutrition, cancer, metabolic medicine, immune health, regenerative medicine, AI and digital health. Quick Answer This page routes you to the right guide across the OneDayMD network. Pick the question closest to yours, open the matching master guide, then drill into the specific study, therapy, supplement or condition. Master guides are maps, not treatment plans: check each claim’s evidence tier and regulatory status, and take decisions to a licensed clinician. On this page Start Here · Core Health Hubs · Cancer & Oncology · Nutrition & Supplements · Longevity · GLP-1 & Metabolic Health · DMSO · Regene...

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: November 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of November 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side e...